Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction